Novo Nordisk is trading at $46.05, down -3.08%, after Citi reiterated its sell rating, citing slowing GLP-1 prescriptions.
- Citi also cited a 265 Danish krone target; recent Deutsche Bank concerns about the company’s growth trajectory may be adding pressure.
- Broader markets are mixed, so the decline appears primarily company-specific rather than index-driven.
- The September 4, 2026 decline follows a difficult recent period focused on prescription momentum and competitive risks; the quantum-chip announcement does not explain the drop.